HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

PHY 906

a modulator of chemotherapy in patients with advanced colorectal cancer
Also Known As:
PHY906
Networked: 19 relevant articles (3 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Cheng, Yung-Chi: 11 articles (01/2015 - 01/2007)
2. Jiang, Zaoli: 9 articles (01/2015 - 01/2007)
3. Liu, Shwu-Huey: 8 articles (01/2015 - 01/2007)
4. Lam, Wing: 5 articles (01/2015 - 08/2010)
5. Bussom, Scott: 5 articles (01/2015 - 08/2010)
6. Guan, Fulan: 4 articles (01/2015 - 08/2010)
7. Chu, Edward: 4 articles (01/2014 - 10/2009)
8. Saif, Muhammad Wasif: 3 articles (02/2014 - 01/2008)
9. Li, Anyuan: 2 articles (02/2015 - 12/2010)
10. Qi, Fanghua: 2 articles (02/2015 - 12/2010)

Related Diseases

1. Neoplasms (Cancer)
2. Pancreatic Neoplasms (Pancreatic Cancer)
04/10/2012 - "These findings have been examined in clinical studies for colorectal, liver, and pancreatic cancers when PHY906 is used as an adjuvant to chemotherapy and the results were promising; i.e. "
02/01/2014 - "First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer."
02/01/2014 - "Patients with pancreatic cancer and an Eastern Cooperative Oncology Group performance status of 0-2 received PHY906 and capecitabine. "
02/01/2014 - "We conducted this phase II study to explore the efficacy of capecitabine and PHY906 in patients with advanced pancreatic cancer who were previously treated with gemcitabine-based regimens. "
01/01/2008 - "The studies discussed here include the following: i) a phase I study of a chemotherapy doublet gemcitabine plus capecitabine, combined with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma (abstract #141); ii) a phase II study of gemcitabine, bevacizumab, and erlotinib in locally advanced and metastatic adenocarcinoma of the pancreas (abstract #151); iii) final results of the multicenter phase II study on gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer (abstract #198); iv) interim results from a phase II study of volociximab in combination with gemcitabine in patients with metastatic pancreatic cancer (abstract #142); v) a pilot study of combination chemotherapy with S-1 and irinotecan for advanced pancreatic cancer (abstract #155); vi) a multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer (abstract #212); vii) a phase I/II study of PHY906 plus capecitabine in patients with advanced pancreatic carcinoma (abstract #260); and viii) the final results of a phase II trial of Genexol-PM(R), a novel cremophor-free, polymeric micelle formulation of paclitaxel in patients with advanced pancreatic cancer (abstract #269). "
3. Colorectal Neoplasms (Colorectal Cancer)
4. Vomiting
5. Diarrhea

Related Drugs and Biologics

1. capecitabine (Xeloda)
2. irinotecan (Camptosar)
3. gemcitabine
4. Fluorouracil (Carac)
5. Paclitaxel (Taxol)
6. volociximab
7. bevacizumab
8. erlotinib (CP 358,774)
9. S 1 (combination)
10. cremophor

Related Therapies and Procedures

1. Homologous Transplantation (Allograft)
2. Heterologous Transplantation (Xenotransplantation)
3. Drug Therapy (Chemotherapy)
4. Chinese Traditional Medicine (Traditional Chinese Medicine)
5. Combination Drug Therapy (Combination Chemotherapy)